<div id="readability-page-1" class="page"><div id="parent_top_div">In a market shaped by global tensions and shifting sector dynamics, brokerage firm Prabhudas Lilladher (PL Capital) is advising investors to stay grounded—but not passive. At its recent PL Alpha: India View webinar, the firm brought together senior research and advisory voices to decode what lies ahead for Indian equities. The message was clear: brace for volatility, but don’t lose sight of India’s structural strength. According to Amnish Aggarwal, Co-Head – Institutional Equities, the past few weeks have been marked by sharp swings, largely driven by rising geopolitical tensions involving the US, Israel, and Iran. Yet, India has held up relatively well. Policy interventions—such as cuts in oil taxes—have helped cushion immediate shocks. But Aggarwal cautioned that the real impact may still be building beneath the surface. Higher crude prices could trigger second-order effects, pushing inflation higher in the coming months and potentially forcing a reset in growth and earnings expectations. For investors, that means one thing: don’t confuse short-term stability with long-term immunity. Advisory view: Focus on structural themes and stock opportunities: Vikram Kasat, Vikram Kasat (Head –Advisory) From an advisory standpoint, Vikram Kasat, Head – Advisory, highlighted a shift in how capital is being deployed. Instead of broad-based bets, investors—especially HNIs and institutions—are gravitating toward high-conviction, theme-driven opportunities. Key sectors in focus include: <ul> <li> Logistics, powered by e-commerce growth</li> <li> Ethanol, backed by government blending policies</li> <li> Healthcare, offering defensive stability</li> </ul> At the same time, newer-age themes are gaining traction: <ul> <li> Artificial intelligence</li> <li> Robotics</li> <li> Specialized manufacturing</li> </ul> This signals a deeper transition in markets—from cyclical chasing to structural investing. Markets in a Holding Pattern On the technical side, the outlook is more measured. Vaishali Parekh (Technical Research) and Shilpa Rout (Derivatives Research) pointed to a range-bound market, with indices like Nifty moving within a wide band as investors wait for clearer triggers. <ul> <li> Defined support and resistance levels are in play</li> <li> Momentum is selective, not broad-based</li> </ul> Sectorally: Metals, banks, and autos are showing strength Textiles and chemicals may be nearing a turnaround phase In other words, this isn’t a market for blanket bets—it’s a market for precision. Sectoral strategy: Defensive resilience and cyclical recovery plays Throughout the deliberations, the following two-pronged investment strategy emerged as key: Defensive posture in industries like pharmaceuticals and utilities during uncertain times Cyclical play in capital goods, metals, cement, and engineering, especially in case of de-escalation in geopolitics Capital goods, defense, and infra-related sectors remain strong structural growth bets. Cautious optimism amid uncertainty It is important to be careful of international events that may affect issues like inflation, fiscal deficits, and profit margins through their spill-over effects. However, despite some hitches encountered during the discussion, the experts managed to communicate critical aspects of their strategies effectively. PL Capital’s core message to investors is nuanced but actionable: Stay cautious, because global risks—from inflation to fiscal pressures—are real Stay opportunistic, because India’s macro fundamentals remain strong The current market isn’t about aggressive risk-taking or complete withdrawal. It’s about: <ul> <li> Choosing quality over quantity</li> <li> Maintaining diversification</li> <li> Being selective with sectors and themes</li> </ul></div></div>

159615

588130

In a recent webinar, brokerage firm Prabhudas Lilladher (PL Capital) advised investors to remain cautious yet opportunistic amid global tensions affecting markets. Experts highlighted the importance of focusing on structural themes and high-conviction investments, particularly in sectors like logistics, ethanol, and healthcare. They noted that while India has shown resilience, rising crude prices could impact inflation and growth expectations. The market is currently range-bound, requiring precision in investment strategies, with a dual focus on defensive sectors and cyclical recovery plays. Overall, the message emphasizes quality over quantity and selective sector engagement.

Business Standard

VanEck Biotech ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

ISHRS MSCI India

Avantis Emerging Markets Equity ETF

VG Health

iShares MSCI China

GX INDIA TOP 10

Guotai CSI Bio-medicine ETF

SPDR S&P Em Mkt Dvd

ISHARES INDIA

CAM MSCIINDIA

ChinaAMC SSE Health Care ETF Initiating Fund

iShares MSCI EM Ex-China

VG Em Mkts

Proshares UltraShort Nasdaq Biotech

FIL Ltd.

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Tianhong CNI BIOMEDICINE ETF

SPDR S&P Em Asia

iShares US Pharma

Proshares Ultra Nasdaq Biotech

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

iShares MSCI Em

Health Care Select Sector SPDR

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Wisdomtree EM High Dividend Fund

E Fund CSI 300 Health Care ETF

Dimensional Emerging Markets Value ETF

iShares Core MSCI EM

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Direxion S&P Biotech Bull 3X

China Merchants CSI Biotechnology Theme ETF

BlackRock, Inc.

Schw Em Mkt

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ALPS Medical Breakthrough

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

CAM MSCIINDIA-R

Avantis Emerging Markets Value ETF

Bosera Hang Seng Health Care ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

Penghua CSI HK Connect Health Care Composite ETF

iShares Biotechnology ETF

SPDR S&P Biotech

E Fund Hang Seng SCHK Innovative Drug ETF

iShares MSCI Emerging Mkts Val Fac ETF

Direxion S&P Biotech Bear 3X

iShares MSCI EM Market Asia

Invesco Nasdaq Biotechnology ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

iShares Emerging Markets Equity Factor ETF

SPDR Em Mkt

CAM MSCIINDIA-U

Where should you invest in 2026? Experts at PL Capital decode the best bets